Loading…
← CockpitCompetitor Analysis › RLAY Relay Therapeutics, Inc.Open in the cockpit ↗

Relay Therapeutics, Inc.RLAYCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Uses computational modeling of protein motion to design precision oncology and genetic disease drugs.

Momentum neutral 54
Mkt cap
$3.65B
US dollars, full cap
Free float
78%
of shares outstanding
$/day
$48.0M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 13.8%
Hurdle
n/a
no reverse DCF
Next earnings
99 days
25 Feb 2027
Close · USD$16.51
1D+0.2%
1W-16.3%
1M-10.5%
3M-16.2%
6M+26.8%
YTD+95.2%
1Y+149.4%
ATR %6.8%
Beta1.69
52w lowhigh22.4% off high

What Relay Therapeutics does

Uses computational modeling of protein motion to design precision oncology and genetic disease drugs.

Has no approved product and so no sales; spending is funded by money raised from investors and by occasional payments from drug-company partners. Everything hangs on trial results for its lead breast-cancer drug candidate, RLY-2608, which is why each data release moves the company more than any financial result.

Products and services

  • RLY-2608 (PI3K inhibitor, breast cancer)
  • Pipeline in FGFR2 and other targets

Customers

  • Oncologists/cancer centers (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Computationally-driven precision…

What could go right

  • Pivotal trial data readouts
  • Platform-driven pipeline expansion

What could go wrong

  • Clinical trial failure risk
  • High R&D cash burn

Moat: narrow (IP / patents, process know-how, data). Proprietary protein-motion computing platform aids differentiated drug design, though still pre-revenue.

Headquarters: Cambridge, Massachusetts, US · Founded: 2016 · Employees: 192

Named competitors

Relay Therapeutics at a glance

Size Relay Therapeutics (RLAY) is a United States Health Care company (Biotechnology) with a market value of $3.65B, the 1400th largest of 3,085 United States companies the cockpit tracks. Shares closed at $16.51 on 18 Nov 2026.

Performance Over six months the shares gained 26.8%, against -3.3% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue grew 23.9% over the last twelve months (peer median +6.3%); the operating margin is -3,094.6% (peer median -1.4%).

Valuation It trades at 273.1× enterprise value to sales against a peer median of 8.3× (2nd most expensive of 16).

Short interest Short interest is 19.8% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026RLAY 121Peer median 96
Six months, rebased to 100: Relay Therapeutics against the median of its 20 peers (local-currency closes).

Relay Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$10.3M$15.4M$10.0M$25.5M$1.38M
Revenue growth—+53%-61%+1,750%—
Gross profit$8.61M$11.8M$4.54M$20.3M-$2.75M
EBITDA-$319M-$299M-$380M-$374M-$307M
Net income-$294M-$276M-$338M-$342M-$291M
Free cash flow-$214M-$236M-$251M-$304M-$239M
Capital expenditure$1,000$410,000$2.02M$4.13M$9.06M
Total debt$27.0M$32.5M$48.5M$53.5M$57.7M

Quarterly statements and history in the cockpit →

Relay Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%+150%-20%0%+20%603127ABCLTNGXIRON600161IOVACRSP66966919ELVN002007VIRP603392XERSADMATLXDNLI000661RLAY6-month return →1-month return →
Up and to the right = strong over both horizons. Relay Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%0×2,000×4,000×6,000×603127ABCL600161IOVACRSP69190020076033921530XERSRLAYRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Relay Therapeutics is the large dot.

Relay Therapeutics competitors and peer comparison

Head to head with its named competitors (RLAY vs SDGR vs RXRX vs IDYA)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Relay Therapeutics RLAY$3.65B+27%+24%-3,095%273.1×n/a
Schrodinger SDGR$2.04B+127%+5%-50%6.6×n/a
Recursion Pharmaceuticals RXRX$1.76B-5%+56%-725%18.8×n/a
IDEAYA Biosciences IDYA$2.56B-11%-83%-1,267%48.0×n/a

How Relay Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Relay Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureRLAYPeer medianRank in peer set
1-month return-10.5%-4.9%7th lowest of 21
6-month return+26.8%-3.3%6th highest of 21
Distance from 52-week high-22.4%-32.6%5th highest of 21
Revenue growth (TTM)+23.9%+6.3%6th highest of 16
Operating margin-3,094.6%-1.4%2nd lowest of 16
EV / Sales273.1×8.3×2nd most expensive of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Relay Therapeutics RLAYUnited States$3.65B+27%+24%-3,095%273.1×n/an/a
Joinn Laboratories (China) 603127.SSChina$3.67B-6%+12%-4%11.8×n/an/a
AbCellera Biologics ABCLUnited States$3.60B+141%+92%-298%43.4×n/an/a
Tango Therapeutics TNGXUnited States$3.71B+4%-100%n/an/an/an/a
Disc Medicine IRONUnited States$3.55B+16%n/an/an/an/an/a
Beijing Tiantan Biological Products 600161.SSChina$3.47B-13%-13%21%4.5×2.2%+12.5%
Iovance Biotherapeutics IOVAUnited States$3.46B+111%+51%-61%8.3×n/an/a
CRISPR Therapeutics CRSPUnited States$3.90B-17%-34%-2,059%95.6×n/an/a
Lin BioScience 6696.TWOTaiwan$3.98B+305%n/an/an/an/an/a
Caliway Biopharmaceuticals 6919.TWTaiwan$3.32B-25%-54%-6,983%6,626.2×n/an/a
Enliven Therapeutics ELVNUnited States$3.30B+7%n/an/an/an/an/a
Hualan Biological Engineering 002007.SZChina$3.20B-17%-11%17%5.3×15.8%-1.8%
Virbac VIRP.PAFrance$3.20B-4%+4%15%2.1×5.8%+9.4%
Beijing Wantai Biological Pharmacy Enterprise 603392.SSChina$4.20B-43%+8%-35%12.7×n/an/a
3SBio 1530.HKHong Kong$4.28B-31%+102%61%0.9×n/an/a
Xeris Biopharma XERSUnited States$3.10B+173%+38%13%8.7×29.5%+70.2%
ADMA Biologics ADMAUnited States$3.01B+58%+6%45%6.0×-0.8%+64.6%
Telix Pharmaceuticals TLX.AXAustralia$2.99B-2%+27%-1%3.8×n/an/a
Dyne Therapeutics DYNUnited States$2.97B-10%n/an/an/an/an/a
Denali Therapeutics DNLIUnited States$2.95B-2%n/a-2,488%115.4×n/an/a
Changchun High-Tech Industry (Group) 000661.SZChina$4.52B-13%-18%-1%2.8×32.4%+7.1%

Questions

Who are Relay Therapeutics's main competitors?
Named competitors: Schrodinger (SDGR), Recursion Pharmaceuticals (RXRX), Ideaya Biosciences (IDYA). The cockpit's measured peer set (industry) also includes Joinn Laboratories (China) (603127.SS), AbCellera Biologics (ABCL), Tango Therapeutics (TNGX), Disc Medicine (IRON), Beijing Tiantan Biological Products (600161.SS), Iovance Biotherapeutics (IOVA).
Is Relay Therapeutics expensive compared with its peers?
On ev / sales it trades at 273.1× against a peer median of 8.3×, 2nd most expensive of 16 in its peer set.
How has Relay Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +26.8% against -3.3% for the median peer; over one year +149.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.